Published in Cesk Pediatr on June 01, 1990
Interactions of human cytomegalovirus with human fibroblasts. J Bacteriol (1966) 2.00
Thymidine-kinase in cytomegalovirus infected cells. Arch Virol (1976) 1.96
Temperature-sensitive mutants of herpes simplex virus. Virology (1970) 1.83
Correlation between infectivity and physical virus particles in human cytomegalovirus. J Bacteriol (1966) 1.71
Thermoinactivation of human cytomegalovirus. J Bacteriol (1966) 1.56
Human cytomegalovirus: properties of the complement-fixing antigen. J Immunol (1966) 1.44
Antibodies in human sera to soluble and viral antigens found in Burkitt lymphoma and other lymphoblastoid cell lines. J Natl Cancer Inst (1970) 1.43
WHO collaborative studies on poliovirus type 3 strains isolated during the 1968 poliomyelitis epidemic in Poland. Bull World Health Organ (1972) 1.42
Ribonucleotides linked to DNA of herpes simplex virus type 1. J Virol (1974) 1.28
Papovaviridae. Intervirology (1974) 1.26
Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer (1984) 1.14
Association of some supraglottic laryngeal carcinomas with EB virus. Int J Cancer (1983) 1.07
Studies on the growth of herpes simplex virus in lymphoblastoid cells. Acta Virol (1971) 1.06
Increased oncogenicity and synthesis of herpesvirus antigens in hamster cells exposed to herpes simplex type-2 virus. J Natl Cancer Inst (1973) 1.05
Sero-epidemiology of the Epstein-Barr virus: preliminary analysis of an international study - a review. IARC Sci Publ (1975) 1.03
Replicating DNA of herpes simplex virus type 1. Intervirology (1976) 1.03
Presence of Epstein-Barr virus DNA in carcinomas of the palatine tonsil. J Natl Cancer Inst (1984) 1.00
Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells. Virology (2001) 0.98
Relationship between Epstein-Barr virus-determined complement-fixing antigen and nuclear antigen detected by anticomplement fluorescence. J Natl Cancer Inst (1974) 0.97
Absence of cytomegalovirus DNA from adenocarcinoma of the colon. Intervirology (1980) 0.92
Longitudinal follow-up of antibody response to selected antigens of human papillomaviruses and herpesviruses in patients with invasive cervical carcinoma. Int J Cancer (2000) 0.91
The use of an in vitro test of delayed type hypersensitivity for the detection of specific tumor antigen of transplantation type induced by SV 40 virus. Z Immunitatsforsch Allerg Klin Immunol (1968) 0.91
Replication of cytomegalovirus in human epitheloid diploid cell line. Arch Virol (1976) 0.90
Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol (1999) 0.89
Phosphonylmethyl ethers of acyclic nucleoside analogues: inhibitors of HSV-1 induced ribonucleotide reductase. Antiviral Res (1990) 0.89
Comparison of genetic properties of influenza viruses before and after repeated passages in monkey kidney cell culture. Acta Virol (1968) 0.88
Absence of cytomegalovirus, Epstein-Barr virus, and papillomavirus DNA from adenoma and adenocarcinoma of the colon. Acta Virol (1988) 0.88
Preparation of antisera against the S antigen of influenza A virus by immunization of guinea pigs with internal S antigen. Arch Gesamte Virusforsch (1967) 0.87
Comparison of ELISA and western blotting for human papillomavirus type 16 E7 antibody determination. J Gen Virol (1991) 0.87
Determination of herpes simplex virus type-specific antibodies by solid-phase RIA on Helix pomatia lectin-purified antigens. J Infect Dis (1984) 0.87
Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation. Arch Virol (1984) 0.87
Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int J Cancer (1984) 0.86
Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J Gen Virol (1990) 0.86
Properties of a new type 3 attenuated poliovirus. VI. Alimentary tract resistance in children fed previously with type 3 Sabin vaccine to reinfection with homologous and heterologous type 3 attenuated poliovirus. Arch Gesamte Virusforsch (1967) 0.86
Variation in neurovirulence of NWS influenza virus after repeated passages in different tissue culture systems. I. Derivation and neurotropic activity of NWS virus lines. Arch Gesamte Virusforsch (1968) 0.86
A new type 3 attenuated poliovirus for possible use in oral poliovirus vaccine. Prog Med Virol (1967) 0.85
Human papillomavirus infection and cervical carcinoma. Clin Obstet Gynecol (2000) 0.85
Serological response to HPV16 in CIN-III and cervical cancer patients. Case-control studies in Spain and Colombia. Int J Cancer (1996) 0.85
Multiplicity reactivation in UV-irradiated herpes simplex type 1 virus. Intervirology (1973) 0.85
Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. J Clin Oncol (1997) 0.84
Linkage between reproductive capacity at increased temperature and neurotropic activity in A-NWS HONi (HON1) influenza virus. Infect Immun (1974) 0.84
Properties of a new type 3 attenuated poliovirus. V. Neurovirulence tests in monkeys after a passage through the human alimentary tract. Arch Gesamte Virusforsch (1965) 0.83
Effect of 3-beta-hydroxysteroid dehydrogenase gene deletion on virulence and immunogenicity of different vaccinia viruses and their recombinants. Arch Virol (1998) 0.83
Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them. Vaccine (1995) 0.83
Antibodies to EB virus capsid antigen and to soluble antigen of lymphoblastoid cells in infectious mononucleosis patients. Int J Cancer (1972) 0.83
Prevalence of antibodies to human papillomaviruses in the general population of the Czech Republic. Int J Cancer (1998) 0.83
Herpes simplex type 2 virus and cervical neoplasia. Adv Cancer Res (1987) 0.83
Presence of Epstein-Barr virus DNA in tonsillar tissues. Acta Virol (1981) 0.83
Plaque formation by NWS influenza virus in a human diploid cell strain. Acta Virol (1967) 0.83
Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. Br J Cancer (2001) 0.82
Some properties of the soluble (S) antigen of cultured lymphoblastoid cell lines. Arch Gesamte Virusforsch (1970) 0.82
Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int J Oncol (1999) 0.82
Clinical reactivity and immunogenicity of hemagglutinin influenza vaccine. I. Clinical reactions, hemagglutination-inhibiting and strain and type-specific complement-fixing antibody responses in subjects aged 3-6, 16-17 and 27-50 years. Arch Gesamte Virusforsch (1972) 0.82
Structure of herpes simplex virus DNA: topography of the molecule. I. Absence of circularly permuted sequences. Virology (1975) 0.82
Prospective study on cervical neoplasia: presence of HPV DNA in cytological smears precedes the development of cervical neoplastic lesions. Sex Transm Infect (2003) 0.81
Electron microscopy of binding of Epstein-Barr virus (EBV) nuclear antigen (EBNA-1) to EBV DNA. Virology (1987) 0.81
Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. J Infect Dis (1994) 0.81
Effects of n-butyrate on Epstein-Barr virus-carrying lymphoma lines. J Gen Virol (1982) 0.81
Genetic interaction between two influenza A-WS virus mutants. II. Genetic interaction between NWS-D and WS-MK viruses in human diploid cells and hamster embryo fibroblasts. Acta Virol (1971) 0.81
Production and some properties of neutralizing antigens of herpes simplex virus. Acta Virol (1977) 0.81
Genetic interaction between two influenza A-WS virus mutants. I. Characterization of the mutants. Acta Virol (1971) 0.81
Ultrastructural changes induced by influenza viruses in permissive and nonpermissive cells. Virology (1977) 0.81
Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol (2003) 0.80
Demonstration of Epstein-Barr virus in malignant non-Hodgkin's lymphomas. Oncology (1986) 0.80
Relationship between Epstein-Barr virus nuclear antigen and DNA genome number in superinfected and induced lymphoblastoid cell lines. J Gen Virol (1983) 0.80
Genetic recombination between plaque-purified mutants of influenza A-NWS and A-2-Singapore viruses. Arch Gesamte Virusforsch (1970) 0.80
The nature of adenovirus persistence in human adenoid vegetations. Arch Virol (1975) 0.80
Variation in neurovirulence of NWS influenza virus after repeated passages in different tissue culture systems. II. Correlation between neurovirulence and some other genetic markers. Arch Gesamte Virusforsch (1968) 0.80
Clinical reactivity and immunogenicity of hemagglutinin influenza vaccine. II. Clinical reactions, hemagglutination-inhibitiong and strain and type-specific complement-fixing antibody responses in infants. Arch Gesamte Virusforsch (1972) 0.80
Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment. Folia Biol (Praha) (2006) 0.79
Immunogenicity of dendritic cell-based HPV16 E6/E7 peptide vaccines: CTL activation and protective effects. Folia Biol (Praha) (2004) 0.79
Development of antibodies against viral and tumor antigens of papovavirus SV40 in monkeys. Proc Soc Exp Biol Med (1967) 0.79
Inhibitory effect of herpes simplex virus type 1 on type 2 virus replication. J Gen Virol (1976) 0.79
Blocking of acid-fixed nuclear binding of Epstein-Barr virus nuclear antigen (EBNA) by different DNA species. J Gen Virol (1979) 0.79
Presence of antibody reactive with synthetic peptide derived from L2 open reading frame of human papillomavirus types 6b and 11 in human sera. Acta Virol (1990) 0.79
Immunogenicity of subviral herpes simplex virus preparations. I. Formation of neutralizing antibodies in different animal species after administration of herpes simplex virus solubilized antigens. Arch Virol (1979) 0.79
Some immunological characteristics of subjects suffering from frequent herpes simplex virus recrudescences. Acta Virol (1989) 0.78
Study of Epstein-Barr virus-determined nuclear antigen (EBNA) by chromatography on fixed cell nuclei. Int J Cancer (1978) 0.78
Immunogenicity of a subviral herpes simplex type 1 preparation: reduction of recurrent disease in mice. Arch Virol (1982) 0.78
In vitro and in vivo effects of reovirus on HPV16-transformed mice cells. Neoplasma (2010) 0.78
Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors. Folia Biol (Praha) (2003) 0.78
Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant. J Gen Virol (1991) 0.78
Epidemiology of the Epstein-Barr virus infection and associated tumors in man. Bibl Haematol (1975) 0.78
Presence and type specificity of papillomavirus antibodies demonstrable by immunoelectron microscopy tests in samples from patients with warts. J Gen Virol (1990) 0.78
Morphological changes in BHK-21 cells infected with S-N (H2N1) influenza virus. Arch Gesamte Virusforsch (1973) 0.78
Correlation between the presence of anti HPV33 VLP antibodies and HPV DNA in cervical neoplasia patients. Arch Virol (1997) 0.78
Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine (1988) 0.78
DNA vaccine against Friend erythroleukaemia virus. Folia Biol (Praha) (2002) 0.77
Use of polyclonal rabbit antibodies for detection of the bcr-abl fusion zone in cells transfected with experimental bcr-abl DNA vaccines. Int J Oncol (2005) 0.77
Cross-reactivity of murine and hamster IL-2 mitogenic signal. Immunol Lett (1996) 0.77
Properties of Syrian hamster cells transformed by human papillomavirus type 16. Acta Virol (1997) 0.77
Procedure for refolding and purification of recombinant proteins from Escherichia coli inclusion bodies using a strong anion exchanger. J Chromatogr B Biomed Appl (1994) 0.77
Determination of virus-specific antigens in extracts from herpes simplex virus-infected cells by a Cr release inhibition test. Infect Immun (1978) 0.77
Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I. Vaccine (1996) 0.77